Corvus Pharmaceuticals is developing the drug soquelitinib for the treatment of moderate to severe atopic dermatitis (eczema).[1][3][4] This is a placebo-controlled, randomized, double-blind, phase 1 study to enroll a total of 64 patients in four cohorts at 12 sites in the US.[1][3][4] In cohort 1, 12 patients received 100 mg twice daily and 4 patients placebo, in cohort 2 7 patients received 200 mg once daily and 3 patients placebo.[1][3] Data from 26 patients showed that 26% of those treated achieved an IGA of 0 or 1 and 37% an EASI of 75, while no patients on placebo achieved these goals.[1] In Cohort 1, mean EASI score reduction was 55.9% at 28 days (n=12) versus 27% on placebo and 69.1% at 58 days (n=10) versus 19.1% on placebo.[2] Nine of 12 patients in cohort 1 achieved EASI 50 at 28 days, including three with EASI 75 and one with EASI 90.[2] All patients in cohort 2 completed 28 days of treatment without significant safety issues or laboratory abnormalities; full results are expected in the second quarter of 2025.[1][3]